Your Good Partner in Biology Research

Rat fibroblast growth factor 23 (FGF23) ELISA Kit

  • 中文名称:
    大鼠成纤维细胞生长因子23(FGF23)酶联免疫试剂盒
  • 货号:
    CSB-E12170r(1)
  • 规格:
    96T/48T
  • 价格:
    ¥3600/¥2500
  • 其他:

产品详情

  • 产品描述:
    CUSABIO专用于科研领域的大鼠成纤维细胞生长因子23(FGF23)酶联免疫检测试剂盒(货号:CSB-E12170r(1)),采用双抗体夹心法定量检测样本中FGF23浓度。FGF23是调控磷代谢和维生素D代谢的关键因子,在慢性肾病、骨骼疾病等病理生理机制研究中具有重要价值。试剂盒适用于检测血清、血浆、细胞培养上清液及组织匀浆样本,检测灵敏度达15.6 ng/mL,线性范围覆盖15.6-1000 ng/mL,可精准反映不同实验条件下FGF23的表达水平变化。该试剂盒经过严格验证,具备高特异性和重复性,96孔板预包被抗体的设计简化操作流程,配合优化后的孵育体系可在4.5小时内完成检测,适用于体外实验模型构建、疾病机制研究以及药物干预效果评估等科研场景。配套提供标准品、检测抗体及显色底物等完整组分,支持科研人员高效开展内分泌代谢相关的基础研究。
  • 别名:
    Fgf23Fibroblast growth factor 23 ELISA Kit; FGF-23 ELISA Kit
  • 缩写:
  • Uniprot No.:
  • 种属:
    Rattus norvegicus (Rat)
  • 样本类型:
    serum, plasma, cell culture supernates, tissue homogenates
  • 检测范围:
    15.6 ng/mL-1000 ng/mL
  • 灵敏度:
    3.9 ng/mL
  • 反应时间:
    1-5h
  • 样本体积:
    50-100ul
  • 检测波长:
    450 nm
  • 研究领域:
    Signal Transduction
  • 测定原理:
    quantitative
  • 测定方法:
    Sandwich
  • 精密度:
    Intra-assay Precision (Precision within an assay): CV%<8%  
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%  
    Three samples of known concentration were tested in twenty assays to assess.
  • 标准曲线:

    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

     

    ng/ml OD1 OD2 Average Corrected
    1000 2.563 2.456 2.510 2.337
    500 1.971 2.001 1.986 1.813
    250 1.243 1.289 1.266 1.093
    125 0.876 0.791 0.834 0.661
    62.5 0.486 0.472 0.479 0.306
    31.2 0.354 0.361 0.358 0.185
    15.6 0.264 0.257 0.261 0.088
    0 0.176 0.169 0.173  
  • 数据处理:
  • 货期:
    3-5 working days

产品评价

靶点详情

  • 最新研究进展:
    成纤维生长因子23(FGF23)是一种重要的内分泌蛋白,主要在骨骼和肾脏中合成,调节钙磷代谢。最近的研究表明,FGF23 不仅与骨代谢异常相关,而且还与心血管、肾脏、免疫系统等多种疾病有关。例如,高水平的 FGF23 与慢性肾脏病进展、心血管疾病、骨质疏松等疾病密切相关。FGF23 的研究不断深入,为相关疾病的治疗和预防提供了新的思路。
  • 功能:
    Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Regulator of vitamin-D metabolism. Negatively regulates osteoblasts differentiation and matrix mineralization. Acts directly on the parathyroid to decrease PTH secretion. Upregulates EGR1 expression in the presence of KL.
  • 基因功能参考文献:
    1. Increases in plasma erythropoietin and erythropoietin receptor activation are mechanisms implicated in the increase of plasma FGF23 in acute kidney injury. PMID: 29395333
    2. In chronic kidney disease (CKD) rat models, FGF23 mRNA is expressed in the kidney, and the FGF23 protein is expressed at high levels in osteopontin-positive renal tubule epithelium cells likely via TGFbeta1 stimulation. FGF23 produced in the kidney might contribute to P metabolism in subjects with CKD. PMID: 29518087
    3. High FGF23 expression is associated with cardiac hypertrophy. PMID: 28339837
    4. The only direct contribution of the injured kidney to circulating FGF23 levels in uremia appears to be reduced renal extraction of bone-derived FGF23. PMID: 28341272
    5. Osteoblast Fgf23 transcription is upregulated by increase in the cytosolic Ca(2+) activity. Fgf23 transcription is decreased by Orai inhibitors and Orai1 silencing. Fgf23 transcription is lowered by NFkappaB inhibitors. PMID: 26631141
    6. EPO dependent regulation pathway of FGF23 gene expression PMID: 29073196
    7. can directly stimulate hepatic secretion of inflammatory cytokines PMID: 27457912
    8. dietary Mg deficiency causes a rapid increase in circulating levels of FGF23 and renal 24(OH)ase mRNA levels PMID: 27624533
    9. phosphate directly enhances Fgf23 transcription without affecting the stability of Fgf23 messenger RNA. PMID: 25792238
    10. Fgf23 gene transcription was abolished by the actin microfilament-disrupting agent cytochalasin B, as well as by the inhibition of actin-regulating Rac1/PAK1 signaling. PMID: 26878191
    11. Although the molecular link between the cardiac lesion and circulating Fgf23 concentrations remains to be identified, our study has uncovered a novel heart-bone-kidney axis PMID: 25858796
    12. In conclusion, PRL was responsible for the lactation-induced mucosal adaptations, which were associated with compensatory increase in FGF-23 expression probably to prevent calcium hyperabsorption. PMID: 26657069
    13. Data indicate that serum fibroblast growth factor 23 (FGF-23) levels independently correlated with bone volume parameters in rats with experimentally induced chronic kidney disease (CKD). PMID: 26186634
    14. fibroblast growth factor 23 is increased by intravenous phosphate loading in uremic rats PMID: 24625659
    15. The polycystic kidney produces FGF23 but is resistant to its action. PMID: 24402093
    16. FGF23 enhances phosphate-induced vascular calcification by promoting osteoblastic differentiation involving the ERK1/2 pathway in the absence of Klotho deficiency. PMID: 24088960
    17. Ca is not a regulator of acute changes in FGF23 secretion. PMID: 24801007
    18. data suggest that inhibition of FGFR signaling following administration of either pan-FGFR inhibitor or MEK inhibitor interferes with the FGF23 pathway, predisposing animals to hyperphosphatemia PMID: 23872713
    19. In non-iron depleted normal and uremic rats a single high dose of either of two intravenous iron preparations, iron isomaltoside 1000, and ferric carboxymaltose, had no effect on plasma levels of iFGF23 and phosphate for up to seven days. PMID: 24373521
    20. Mg deficiency increases serum FGF-23 levels. PMID: 23608165
    21. a direct and an indirect effect of parathyroid hormone on FGF23 secretion, the latter through changes in calcitriol concentrations PMID: 21525854
    22. late-onset ADHR is the product of gene-environment interactions whereby the combined presence of an Fgf23-stabilizing mutation and iron deficiency can lead to ADHR PMID: 22006328
    23. FGF23 normalizes serum phosphate and decreases 1,25-dihydroxyvitamin D levels in early-stage chronic kidney disease. PMID: 20844473
    24. Serum FGF23 increased in uremic rats treated with paricalcitol but not those treated with cinacalcet. PMID: 20200094
    25. because of a downregulation of the Klotho-FGFR1c receptor complex, an increase of circulating FGF23 does not decrease parathyroid hormone levels in established chronic kidney disease. PMID: 20016468
    26. Data indicate that cleavage at the RXXR motif abrogates FGF23 activity by removing the binding site for the binary FGFR-Klotho complex in the C-terminal region of FGF23, and by generating an endogenous inhibitor of FGF23. PMID: 19966287
    27. a feedback loop exists among serum phosphorus, 1alpha,25(OH)(2)D(3), and FGF-23, in which the novel phosphate-regulating bone-kidney axis integrated with the parathyroid hormone-vitamin D(3) axis in regulating phosphate homeostasis PMID: 15531762
    28. rat UMR-106 osteoblast-like cells were treated with 1,25(OH)(2)D(3) resulted in a dose- and time-dependent stimulation of FGF23 mRNA concentrations. PMID: 16020653
    29. Mineralized tissue cells are a principal source of Fgf23. PMID: 17350357
    30. FGF23 suppressed both parathyroid hormone (PTH) secretion and PTH gene expression PMID: 17992255
    31. These results suggest that the N- and C-terminal domains of FGF23 are responsible for association with cognate FGF receptors and Klotho, respectively, and that these interactions are indispensable for FGF23 activity. PMID: 18442315
    32. Results show that the elevated plasma FGF23 levels in uremic rats reflect the increased expression of FGF23 in bone. PMID: 19339809
    33. estrogens regulate PTH indirectly, possibly through FGF23 PMID: 19628670

    显示更多

    收起更多

  • 亚细胞定位:
    Secreted.
  • 蛋白家族:
    Heparin-binding growth factors family
  • 组织特异性:
    Expressed in the parathyroid.
  • 数据库链接: